

Attachments

Accompanying this response are the following documents:

- (1) Copy of the priority documents for U.S. Patent No. 4,889,919;
- (2) Copy of the Rule 131 Declaration filed in related application Serial No. 07/574,540 (now issued as U.S. Patent No. 5,219,759).

Amendment

In the Claims:

Please amend claims 25-27 as follows:

25. (Three times amended) [Recombinant] A recombinant protein preparation comprising a PDGF A-chain homodimer comprised of two disulfide linked chains, each of said chains comprising the amino acid sequence numbered 87-193, inclusive, of Figure 1, or an analog of said sequence that is substantially homologous and functionally equivalent thereto, wherein said protein preparation is produced in a nonhuman cell such that said protein preparation is free of other human proteins.

26. (Twice amended) [Recombinant] A recombinant protein preparation comprising a PDGF A-chain homodimer comprised of two disulfide linked chains, each of said chains comprising (a) the amino acid sequence numbered 87-196, inclusive, of Figure 1, (b) the amino acid sequence numbered 87 to 196, inclusive, of figure 2 or (c) an analog of (a) or (b) that is substantially homologous and functionally equivalent thereto, wherein said protein

Pub. II
H'
encl.

preparation is produced in a nonhuman cell such that said protein preparation is free of other human proteins.

27. (Twice amended) [Recombinant] A recombinant protein preparation comprising a PDGF A-chain homodimer comprised of two disulfide linked chains, each of said chains comprising the amino acid sequence numbered 87-211, inclusive, of Figure 1, or an analog of said sequence that is substantially homologous and functionally equivalent thereto, wherein said protein preparation is produced in a nonhuman cell such that said protein preparation is free of other human proteins.

Please cancel claim 42 without prejudice and disclaimer and add the following new claims:

--43. (New) The protein preparation of claim 25, further comprising a pharmaceutically acceptable excipient.

44. (New) The protein preparation of claim 26, further comprising a pharmaceutically acceptable excipient.

A²

45. (New) The protein preparation of claim 27, further comprising a pharmaceutically acceptable excipient.

46. (New) A method of treating full or partial wounds comprising administering an effective amount of the protein preparation of claim 43.

47. (New) A method of treating full or partial wounds comprising administering an effective amount of the protein preparation of claim 44.

48. (New) A method of treating full or partial wounds comprising administering an effective amount of the protein preparation of claim 45.

49. (New) The method of claim 46 wherein the preparation is applied topically.

50. (New) The method of claim 47 wherein the preparation is applied topically.

51. (New) The method of claim 48 wherein the preparation is applied topically.

52. (New) The method of claim 46 wherein the wound is cutaneous, dermal, mucosal or epithelial.

53. (New) The method of claim 47 wherein the wound is cutaneous, dermal, mucosal or epithelial.

54. (New) The method of claim 48 wherein the wound is cutaneous, dermal, mucosal or epithelial.--

In the Title:

Please replace the current title with the following:

--RECOMBINANT PDGF A-CHAIN HOMODIMERS AND METHODS OF USE--.